Portal de Periódicos da CAPES

Adverse reactions to gefitinib (Iressa®): Revealing sycosis‐ and pyoderma gangrenosum‐like lesions

2006; Wiley; Volume: 45; Issue: 8 Linguagem: Inglês

10.1111/j.1365-4632.2006.02749.x

1365-4632

Rei Sagara, Amane Kitami, Tokio Nakada, Masafumi Iijima,

Nail Diseases and Treatments

International Journal of DermatologyVolume 45, Issue 8 p. 1002-1003 Adverse reactions to gefitinib (Iressa®): Revealing sycosis- and pyoderma gangrenosum-like lesions Rei Sagara MD , Rei Sagara MD Department of Dermatology, Showa University School of MedicineSearch for more papers by this authorAmane Kitami MD, Amane Kitami MD Department of Dermatology, Showa University School of MedicineSearch for more papers by this authorTokio Nakada MD, Tokio Nakada MD Department of Dermatology, Showa University School of MedicineSearch for more papers by this authorMasafumi Iijima MD, Masafumi Iijima MD Department of Dermatology, Showa University School of MedicineSearch for more papers by this author Rei Sagara MD , Rei Sagara MD Department of Dermatology, Showa University School of MedicineSearch for more papers by this authorAmane Kitami MD, Amane Kitami MD Department of Dermatology, Showa University School of MedicineSearch for more papers by this authorTokio Nakada MD, Tokio Nakada MD Department of Dermatology, Showa University School of MedicineSearch for more papers by this authorMasafumi Iijima MD, Masafumi Iijima MD Department of Dermatology, Showa University School of MedicineSearch for more papers by this author First published: 17 January 2006 https://doi.org/10.1111/j.1365-4632.2006.02749.xCitations: 18 Tokio Nakada Department of Dermatology Showa University School of Medicine 1-5-8, Hatanodai, Shinagawa-ku Tokyo 142-8666 Japan E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Nanney LB, Stoscheck CM, King LE Jr, et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990; 94: 742– 748. 2 Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598– 601. 3 Kobayashi I, Katsumi S, Asada H, et al. Cutaneous side-effects induced by Gefitinib (IressaR). Jpn J Dermatol 2004; 114: 1107– 1113 (in Japanese). 4 Alanko K, Hannuksela M. Mechanisms of drug reactions. Skin reactions to drugs. CRC press, 1998: 17– 24. 5 Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169– 1176. 6 Satoh Y, Hino H. Drug eruption due to Gefitinib (IressaR). Rinsho Hihuka 2004; 58: 28– 32 (in Japanese). 7 Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110– 124. 8 Hay R, Adriaans B. Sycosis. Rook's Textbook of Dermatology, 7th edn. Blackwell Science, 2004: 27.4– 5. Citing Literature Volume45, Issue8August 2006Pages 1002-1003 ReferencesRelatedInformation